TYK2 and systemic lupus erythematosus: Although the Tyk-2 inhibitor, deucravacitinib, showed promise in a recent phase II trial [71], the concern of thromboembolism and cancer risk in post-marketing studies of RA, particularly in older patients with a cardiovascular risk [72], has led to caution of the use of Jakinibs in patients with SLE, who are at augmented risk of malignancy and premature atherosclerosis.